Verastem Sees Phase III Success With PIK3 Inhibitor Dropped By AbbVie

 
• By Joseph Haas

Duvelisib, licensed from Infinity in 2016, reduces risk of disease progression or death compared to Arzerra in a Phase III study in refractory CLL/SLL. Verastem hopes to file an NDA during the first half of 2018.

Risk versus value matrix with pushpins and blur effect. Concept of investment risk assessment.

More from Clinical Trials

More from R&D